Fabricio Klerynton Marchini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fabricio Klerynton Marchini has a total of 303 co-authors. Here are the top co-authors by number of shared publications:
Michel Batista
Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Fiocruz Paraná, Paraná, Brazil
12 shared publications- Marco Aurélio Krieger
Instituto Carlos Chagas, FIOCRUZ, Curitiba, Parana, Brazil
7 shared publications - Fernanda Grande Kugeratski
Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
6 shared publications - Luis Gustavo Morello
Fundação Oswaldo Cruz, Brazil
5 shared publications - Rita de Cássia Pontello Rampazzo
Instituto Carlos Chagas, FIOCRUZ, Curitiba, Parana, Brazil
5 shared publications - Samuel Goldenberg
Fundação Oswaldo Cruz-Fiocruz, Brazil
5 shared publications
Latest Publications
- Open Access
- 7 August 2025
- Published by Wiley in Tropical Medicine & International Health
- Vol. 30 (10) , 1107-1114
Diagnostic Performance of Chimeric Recombinant Antigens of Trypanosoma cruzi for Identifying Chagas Disease in Samples From Rio Grande do Sul
Background: Chagas disease, caused by Trypanosoma cruzi, remains a significant public health challenge in Latin America, with diagnostic limitations hindering control efforts.Aim: Our study aimed to assess the diagnostic performance of four chimeric recombinant T. cruzi antigens (IBMP‐8.1, IBMP‐8.2, IBMP‐8.3 and IBMP‐8.4) in a highly endemic region in southern Brazil.Methods: Serum samples from 333 individuals residing in Canguçu, Rio Grande do Sul, were tested using an in‐house ELISA platform. We assessed the sensitivity, specificity, accuracy, and diagnostic odds ratio (DOR) of individual and combined IBMP antigens through serial and parallel testing strategies.Results: All antigens exhibited 100% specificity and high accuracy (≥ 93.4%), with IBMP‐8.1 and IBMP‐8.4 showing the best overall performance (sensitivities of 80.0% and 76.7%; DORs of 109,136 and 89,659, respectively). Parallel testing using the combinations IBMP‐8.1 + IBMP‐8.3 and IBMP‐8.1 + IBMP‐8.4 achieved ≥ 95% sensitivity and > 99% accuracy.Conclusions: These findings support the use of IBMP chimeric antigens, particularly in combination, as reliable tools for Chagas disease diagnosis and surveillance, and highlight the importance of region‐specific validation to ensure diagnostic equity in diverse endemic settings.
- 7 August 2025
- Published by Wiley in Tropical Medicine & International Health
- Vol. 30 (10) , 1107-1114
Open AccessDiagnostic Performance of Chimeric Recombinant Antigens of Trypanosoma cruzi for Identifying Chagas Disease in Samples From Rio Grande do Sul
Background: Chagas disease, caused by Trypanosoma cruzi, remains a significant public health challenge in Latin America, with diagnostic limitations hindering control efforts.Aim: Our study aimed to assess the diagnostic performance of four chimeric recombinant T. cruzi antigens (IBMP‐8.1, IBMP‐8.2, IBMP‐8.3 and IBMP‐8.4) in a highly endemic region in southern Brazil.Methods: Serum samples from 333 individuals residing in Canguçu, Rio Grande do Sul, were tested using an in‐house ELISA platform. We assessed the sensitivity, specificity, accuracy, and diagnostic odds ratio (DOR) of individual and combined IBMP antigens through serial and parallel testing strategies.Results: All antigens exhibited 100% specificity and high accuracy (≥ 93.4%), with IBMP‐8.1 and IBMP‐8.4 showing the best overall performance (sensitivities of 80.0% and 76.7%; DORs of 109,136 and 89,659, respectively). Parallel testing using the combinations IBMP‐8.1 + IBMP‐8.3 and IBMP‐8.1 + IBMP‐8.4 achieved ≥ 95% sensitivity and > 99% accuracy.Conclusions: These findings support the use of IBMP chimeric antigens, particularly in combination, as reliable tools for Chagas disease diagnosis and surveillance, and highlight the importance of region‐specific validation to ensure diagnostic equity in diverse endemic settings.
- Open Access
- 20 May 2025
- Published by Sechenov University in The BRICS Health Journal
- Vol. 2 (1) , 3-12
Brazilian legislation on innovation policy: a brief history
Innovation is essential for socio-economic progress, particularly in today's fiercely competitive global environment. This article's primary focus is to review the evolution of Brazilian regulations on innovation policy, a subject of intense debate by the government and academic and business institutions. The goal is to review this evolution and dissect the key regulatory frameworks, policies, and initiatives shaping the current scenario. Qualitative research is carried out in three stages: searching and selecting documents, reading and categorizing sources and records, and reviewing relevant information. Since the 2000s, Brazil has promoted legislative reforms to modernize the mechanisms to encourage research and development, such as the Legal Framework for Innovation (2004), the inclusion of the term innovation in the Federal Constitution (2015), the new Legal Framework for Innovation (2016) and the National Policy for Technological Innovation in Health (2017). These changes enhance legal certainty and tax benefits for collaborations between companies and Science, Technology, and Innovation Institutions. Despite the progress, it is still crucial for Brazilian institutions to adopt more robust innovation policies and more effectively align them with national development policies. Recently, the country intensified its innovation efforts by summarizing the Health Economic-Industrial Complex, integrated with the New Industrialization Policy, focused on economic, social, and sustainable development, highlighting public health. Brazil's evolution in innovation policy is a testament to the nation's steadfast commitment to technological and economic progress. While significant strides have been made, greater integration between institutions is imperative to maximize the benefits of innovation.
- 20 May 2025
- Published by Sechenov University in The BRICS Health Journal
- Vol. 2 (1) , 3-12
Open AccessBrazilian legislation on innovation policy: a brief history
Innovation is essential for socio-economic progress, particularly in today's fiercely competitive global environment. This article's primary focus is to review the evolution of Brazilian regulations on innovation policy, a subject of intense debate by the government and academic and business institutions. The goal is to review this evolution and dissect the key regulatory frameworks, policies, and initiatives shaping the current scenario. Qualitative research is carried out in three stages: searching and selecting documents, reading and categorizing sources and records, and reviewing relevant information. Since the 2000s, Brazil has promoted legislative reforms to modernize the mechanisms to encourage research and development, such as the Legal Framework for Innovation (2004), the inclusion of the term innovation in the Federal Constitution (2015), the new Legal Framework for Innovation (2016) and the National Policy for Technological Innovation in Health (2017). These changes enhance legal certainty and tax benefits for collaborations between companies and Science, Technology, and Innovation Institutions. Despite the progress, it is still crucial for Brazilian institutions to adopt more robust innovation policies and more effectively align them with national development policies. Recently, the country intensified its innovation efforts by summarizing the Health Economic-Industrial Complex, integrated with the New Industrialization Policy, focused on economic, social, and sustainable development, highlighting public health. Brazil's evolution in innovation policy is a testament to the nation's steadfast commitment to technological and economic progress. While significant strides have been made, greater integration between institutions is imperative to maximize the benefits of innovation.
- Open Access
- 12 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (4) , 1544
Trypanosomatid Extracellular Vesicles as Potential Immunogens for Chagas Disease
Chagas disease remains a significant public health concern, with limited treatment options and an urgent need for novel preventive strategies. Extracellular vesicles (EVs) from Trypanosoma cruzi have been shown to modulate host immune responses, often favoring parasite persistence. In this study, we characterized EVs derived from the non-pathogenic trypanosomatids Trypanosoma rangeli and Phytomonas serpens and evaluated their potential as immunogens capable of inducing cross-protection against T. cruzi infection. Isolated EVs were characterized by Nanoparticle Tracking Analysis (NTA) and electron microscopy. A comparative proteomic analysis of EVs was performed using Mass Spectrometry-Based Proteomic Analysis (LC-MS/MS). The effects of EVs on immunomodulation and T. cruzi infection were assessed through in vitro and in vivo assays, using peripheral blood mononuclear cells (PBMCs) and BALB/c mice. The proteomic analysis identified shared proteins between the EVs of T. rangeli, P. serpens, and T. cruzi, including immunogenic candidates such as calpain-like cysteine peptidase and elongation factor 2. In vitro, pre-stimulation with the T. rangeli EVs reduced infection rates of the host cells by T. cruzi. In vivo, immunization with the EVs from T. rangeli and P. serpens led to a significant reduction in parasitemia in the BALB/c mice challenged with T. cruzi, though this did not translate into improved survival compared to controls. Interestingly, the EVs from T. cruzi also reduced parasitemia but did not confer protection against mortality. These findings suggest that while non-pathogenic trypanosomatid EVs exhibit potential immunogenic properties and can reduce parasitic load, their efficacy in preventing disease progression remains limited. Further research is needed to explore the mechanisms underlying these effects and to optimize EV-based strategies for protective immunity against Chagas disease.
- 12 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (4) , 1544
Open AccessTrypanosomatid Extracellular Vesicles as Potential Immunogens for Chagas Disease
Chagas disease remains a significant public health concern, with limited treatment options and an urgent need for novel preventive strategies. Extracellular vesicles (EVs) from Trypanosoma cruzi have been shown to modulate host immune responses, often favoring parasite persistence. In this study, we characterized EVs derived from the non-pathogenic trypanosomatids Trypanosoma rangeli and Phytomonas serpens and evaluated their potential as immunogens capable of inducing cross-protection against T. cruzi infection. Isolated EVs were characterized by Nanoparticle Tracking Analysis (NTA) and electron microscopy. A comparative proteomic analysis of EVs was performed using Mass Spectrometry-Based Proteomic Analysis (LC-MS/MS). The effects of EVs on immunomodulation and T. cruzi infection were assessed through in vitro and in vivo assays, using peripheral blood mononuclear cells (PBMCs) and BALB/c mice. The proteomic analysis identified shared proteins between the EVs of T. rangeli, P. serpens, and T. cruzi, including immunogenic candidates such as calpain-like cysteine peptidase and elongation factor 2. In vitro, pre-stimulation with the T. rangeli EVs reduced infection rates of the host cells by T. cruzi. In vivo, immunization with the EVs from T. rangeli and P. serpens led to a significant reduction in parasitemia in the BALB/c mice challenged with T. cruzi, though this did not translate into improved survival compared to controls. Interestingly, the EVs from T. cruzi also reduced parasitemia but did not confer protection against mortality. These findings suggest that while non-pathogenic trypanosomatid EVs exhibit potential immunogenic properties and can reduce parasitic load, their efficacy in preventing disease progression remains limited. Further research is needed to explore the mechanisms underlying these effects and to optimize EV-based strategies for protective immunity against Chagas disease.
- Open Access
- 8 January 2025
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 112 (1) , 89-95
Comparison of Four Chimeric Antigens and Commercial Serological Assays for the Diagnosis of Trypanosoma cruzi Infection
: Chagas disease (CD), a neglected tropical disease caused by Trypanosoma cruzi, is a significant public health issue particularly in Latin America, affecting millions worldwide. Diagnosis is a challenge owing to the genetic diversity of T. cruzi and the complexities involved in selecting antigens for the detection of anti–T. cruzi antibodies. This study evaluated four chimeric recombinant antigens (IBMP-8.1, IBMP-8.2, IBMP-8.3, and IBMP-8.4) designed to enhance diagnostic accuracy by addressing assay variability. We compared the diagnostic performance of these chimeric antigens using indirect ELISA as a diagnostic platform, with three commercial serological assays in Brazil, analyzing 100 serum samples from individuals with confirmed CD and 86 from non-infected controls. The results revealed that all assays and antigens demonstrated an area under the receiver operating characteristic curve of 100%, signifying their exceptional ability to distinguish between CD-positive and CD-negative samples. Notably, the chimeric antigens achieved 100% sensitivity, specificity, accuracy, and kappa index, equaling or surpassing the commercial assays. This research highlights the efficacy of IBMP chimeric antigens as reliable diagnostic tools for CD, suggesting their potential integration into commercial diagnostic platforms to enhance the accuracy and reliability of CD detection.
- 8 January 2025
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 112 (1) , 89-95
Open AccessComparison of Four Chimeric Antigens and Commercial Serological Assays for the Diagnosis of Trypanosoma cruzi Infection
: Chagas disease (CD), a neglected tropical disease caused by Trypanosoma cruzi, is a significant public health issue particularly in Latin America, affecting millions worldwide. Diagnosis is a challenge owing to the genetic diversity of T. cruzi and the complexities involved in selecting antigens for the detection of anti–T. cruzi antibodies. This study evaluated four chimeric recombinant antigens (IBMP-8.1, IBMP-8.2, IBMP-8.3, and IBMP-8.4) designed to enhance diagnostic accuracy by addressing assay variability. We compared the diagnostic performance of these chimeric antigens using indirect ELISA as a diagnostic platform, with three commercial serological assays in Brazil, analyzing 100 serum samples from individuals with confirmed CD and 86 from non-infected controls. The results revealed that all assays and antigens demonstrated an area under the receiver operating characteristic curve of 100%, signifying their exceptional ability to distinguish between CD-positive and CD-negative samples. Notably, the chimeric antigens achieved 100% sensitivity, specificity, accuracy, and kappa index, equaling or surpassing the commercial assays. This research highlights the efficacy of IBMP chimeric antigens as reliable diagnostic tools for CD, suggesting their potential integration into commercial diagnostic platforms to enhance the accuracy and reliability of CD detection.
- Open Access
- 9 October 2024
- Published by Springer Nature in Scientific Data
- Vol. 11 (1) , 1-8
A dataset for developing proteomic tools for pathogen detection via differential cell lysis of whole blood samples
This data descriptor presents a curated dataset for pathogen detection and identification (Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans) directly from whole-blood samples. The dataset was created using differential cell lysis combined with rapid extraction, digestion, and mass spectrometry-based proteomics. Our method offers a rapid diagnostic alternative to traditional culture, enabling timely disease management, such as sepsis. Highlighting our dataset’s uniqueness, it features a three-tier structure: Spectral Libraries of Pathogens for identifying peptide peaks for putative biomarkers; Spiked pathogen in blood MS data for biomarker panel optimization through varied concentration samples; and Parallel Reaction Monitoring (PRM) data from sepsis patients for validating our biomarker panel, achieving 83.3% sensitivity within seven hours without microbial enrichment culture. This dataset serves as a comprehensive reference for bioinformatic tool development and biomarker panel proposals, advancing microbial detection, antimicrobial resistance, and epidemiological studies.
- 9 October 2024
- Published by Springer Nature in Scientific Data
- Vol. 11 (1) , 1-8
Open AccessA dataset for developing proteomic tools for pathogen detection via differential cell lysis of whole blood samples
This data descriptor presents a curated dataset for pathogen detection and identification (Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans) directly from whole-blood samples. The dataset was created using differential cell lysis combined with rapid extraction, digestion, and mass spectrometry-based proteomics. Our method offers a rapid diagnostic alternative to traditional culture, enabling timely disease management, such as sepsis. Highlighting our dataset’s uniqueness, it features a three-tier structure: Spectral Libraries of Pathogens for identifying peptide peaks for putative biomarkers; Spiked pathogen in blood MS data for biomarker panel optimization through varied concentration samples; and Parallel Reaction Monitoring (PRM) data from sepsis patients for validating our biomarker panel, achieving 83.3% sensitivity within seven hours without microbial enrichment culture. This dataset serves as a comprehensive reference for bioinformatic tool development and biomarker panel proposals, advancing microbial detection, antimicrobial resistance, and epidemiological studies.
- Open Access
- 13 July 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (14) , 1514
Comprehensive Study of the IBMP ELISA IgA/IgM/IgG COVID-19 Kit for SARS-CoV-2 Antibody Detection
COVID-19 laboratory diagnosis primarily relies on molecular tests, highly sensitive during early infection stages with high viral loads. As the disease progresses, sensitivity decreases, requiring antibody detection. Since the beginning of the pandemic, serological tests have been developed and made available in Brazil, but their diagnostic performance varies. This study evaluated the IBMP ELISA IgA/IgM/IgG COVID-19 kit performance in detecting SARS-CoV-2 antibodies. A total of 90 samples, including 64 from COVID-19 patients and 26 pre-pandemic donors, were assessed based on time post symptom onset (0–7, 8–14, and 15–21 days). The kit showed 61% sensitivity, 100% specificity, and 72% accuracy overall. Sensitivity varied with time, being 25%, 57%, and 96% for 0–7, 8–14, and 15–21 days, respectively. Similar variations were noted in other commercial tests. The Gold ELISA COVID-19 (IgG/IgM) had sensitivities of 31%, 71%, and 100%, while the Anti-SARS-CoV-2 NCP ELISA (IgG) and Anti-SARS-CoV-2 NCP ELISA (IgM) showed varying sensitivities. The IBMP ELISA kit displayed high diagnostic capability, especially as the disease progressed, complementing COVID-19 diagnosis. Reproducibility assessment revealed minimal systematic and analytical errors. In conclusion, the IBMP ELISA IgA/IgM/IgG COVID-19 kit is a robust tool for detecting anti-SARS-CoV-2 antibodies, increasing in efficacy over the disease course, and minimizing false negatives in RT-PCR COVID-19 diagnosis.
- 13 July 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (14) , 1514
Open AccessComprehensive Study of the IBMP ELISA IgA/IgM/IgG COVID-19 Kit for SARS-CoV-2 Antibody Detection
COVID-19 laboratory diagnosis primarily relies on molecular tests, highly sensitive during early infection stages with high viral loads. As the disease progresses, sensitivity decreases, requiring antibody detection. Since the beginning of the pandemic, serological tests have been developed and made available in Brazil, but their diagnostic performance varies. This study evaluated the IBMP ELISA IgA/IgM/IgG COVID-19 kit performance in detecting SARS-CoV-2 antibodies. A total of 90 samples, including 64 from COVID-19 patients and 26 pre-pandemic donors, were assessed based on time post symptom onset (0–7, 8–14, and 15–21 days). The kit showed 61% sensitivity, 100% specificity, and 72% accuracy overall. Sensitivity varied with time, being 25%, 57%, and 96% for 0–7, 8–14, and 15–21 days, respectively. Similar variations were noted in other commercial tests. The Gold ELISA COVID-19 (IgG/IgM) had sensitivities of 31%, 71%, and 100%, while the Anti-SARS-CoV-2 NCP ELISA (IgG) and Anti-SARS-CoV-2 NCP ELISA (IgM) showed varying sensitivities. The IBMP ELISA kit displayed high diagnostic capability, especially as the disease progressed, complementing COVID-19 diagnosis. Reproducibility assessment revealed minimal systematic and analytical errors. In conclusion, the IBMP ELISA IgA/IgM/IgG COVID-19 kit is a robust tool for detecting anti-SARS-CoV-2 antibodies, increasing in efficacy over the disease course, and minimizing false negatives in RT-PCR COVID-19 diagnosis.
- Open Access
- 17 November 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (22) , 3470
Assessment of Cross-Reactivity of Chimeric Trypanosoma cruzi Antigens with Crithidia sp. LVH-60A: Implications for Accurate Diagnostics
This study focuses on developing accurate immunoassays for diagnosing Chagas disease (CD), a challenging task due to antigenic similarities between Trypanosoma cruzi and other parasites, leading to cross-reactivity. To address this challenge, chimeric recombinant T. cruzi antigens (IBMP-8.1, IBMP-8.2, IBMP-8.3, and IBMP-8.4) were synthesized to enhance specificity and reduce cross-reactivity in tests. While these antigens showed minimal cross-reactivity with leishmaniasis, their performance with other trypanosomatid infections was unclear. This study aimed to assess the diagnostic potential of these IBMP antigens for detecting CD in patients with Crithidia sp. LVH-60A, a parasite linked to visceral leishmaniasis-like symptoms in Brazil. This study involved seven Crithidia sp. LVH-60A patients and three Leishmania infantum patients. The results indicated that these IBMP antigens displayed 100% sensitivity, with specificity ranging from 87.5% to 100%, and accuracy values between 90% and 100%. No cross-reactivity was observed with Crithidia sp. LVH-60A, and only one L. infantum-positive sample showed limited cross-reactivity with IBMP-8.1. This study suggests that IBMP antigens offer promising diagnostic performance, with minimal cross-reactivity in regions where T. cruzi and other trypanosomatids are prevalent. However, further research with a larger number of Crithidia sp. LVH-60A-positive samples is needed to comprehensively evaluate antigen cross-reactivity.
- 17 November 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (22) , 3470
Open AccessAssessment of Cross-Reactivity of Chimeric Trypanosoma cruzi Antigens with Crithidia sp. LVH-60A: Implications for Accurate Diagnostics
This study focuses on developing accurate immunoassays for diagnosing Chagas disease (CD), a challenging task due to antigenic similarities between Trypanosoma cruzi and other parasites, leading to cross-reactivity. To address this challenge, chimeric recombinant T. cruzi antigens (IBMP-8.1, IBMP-8.2, IBMP-8.3, and IBMP-8.4) were synthesized to enhance specificity and reduce cross-reactivity in tests. While these antigens showed minimal cross-reactivity with leishmaniasis, their performance with other trypanosomatid infections was unclear. This study aimed to assess the diagnostic potential of these IBMP antigens for detecting CD in patients with Crithidia sp. LVH-60A, a parasite linked to visceral leishmaniasis-like symptoms in Brazil. This study involved seven Crithidia sp. LVH-60A patients and three Leishmania infantum patients. The results indicated that these IBMP antigens displayed 100% sensitivity, with specificity ranging from 87.5% to 100%, and accuracy values between 90% and 100%. No cross-reactivity was observed with Crithidia sp. LVH-60A, and only one L. infantum-positive sample showed limited cross-reactivity with IBMP-8.1. This study suggests that IBMP antigens offer promising diagnostic performance, with minimal cross-reactivity in regions where T. cruzi and other trypanosomatids are prevalent. However, further research with a larger number of Crithidia sp. LVH-60A-positive samples is needed to comprehensively evaluate antigen cross-reactivity.
- Open Access
- 14 November 2023
- Published by Elsevier in The Brazilian Journal of Infectious Diseases
- Vol. 27, 103188
LC-ESI-MS/MS NA IDENTIFICAÇÃO DE AGENTES ETIOLÓGICOS DA SEPSE
- 14 November 2023
- Published by Elsevier in The Brazilian Journal of Infectious Diseases
- Vol. 27, 103188
Open AccessLC-ESI-MS/MS NA IDENTIFICAÇÃO DE AGENTES ETIOLÓGICOS DA SEPSE
- Open Access
Validation of the NAT Chagas IVD Kit for the Detection and Quantification of Trypanosoma cruzi in Blood Samples of Patients with Chagas Disease
In the absence of validated biomarkers to control the cure of Chagas disease, PCR-based diagnosis is being used as the main tool for an early indication of therapeutic failure. However, since it is considered a technique of complex reproducibility, mainly due to difficulties in establishing accurate controls to guarantee the quality of the reaction, the use of PCR for Chagas disease diagnosis is restricted to specialized centers. In an effort to disseminate the molecular diagnosis of Chagas disease and its applications, new diagnostic kits based on qPCR have been made available in the market in recent years. Here, we show the results of the validation of the NAT Chagas kit (Nucleic Acid Test for Chagas Disease) for the detection and quantification of T. cruzi in blood samples of patients suspected of Chagas disease infection. The kit, composed of a TaqMan duplex reaction targeting the T. cruzi satellite nuclear DNA and an exogenous internal amplification control, presented a reportable range from 104 to 0.5 parasite equivalents/mL and a limit of detection (LOD) of 0.16 parasite equivalents/mL of blood. In addition, the NAT Chagas kit detected T. cruzi belonging to all six discrete typing units (DTUs—TcI to TcVI), similarly to the in-house real-time PCR performed with commercial reagents, which has been selected as the best performance assay in the international consensus for the validation of qPCR for Chagas disease. In the clinical validation presented here, the kit showed 100% sensitivity and 100% specificity when compared to the consensus in-house real-time PCR assay. Thus, the NAT Chagas kit, which is produced entirely in Brazil under the international standards of good manufacturing practices (GMP), appears as an excellent alternative to enable the molecular diagnosis of Chagas disease in public and private diagnostic centers, as well as to facilitate the monitoring of patients under etiological treatment participating in clinical trials.
Open AccessValidation of the NAT Chagas IVD Kit for the Detection and Quantification of Trypanosoma cruzi in Blood Samples of Patients with Chagas Disease
In the absence of validated biomarkers to control the cure of Chagas disease, PCR-based diagnosis is being used as the main tool for an early indication of therapeutic failure. However, since it is considered a technique of complex reproducibility, mainly due to difficulties in establishing accurate controls to guarantee the quality of the reaction, the use of PCR for Chagas disease diagnosis is restricted to specialized centers. In an effort to disseminate the molecular diagnosis of Chagas disease and its applications, new diagnostic kits based on qPCR have been made available in the market in recent years. Here, we show the results of the validation of the NAT Chagas kit (Nucleic Acid Test for Chagas Disease) for the detection and quantification of T. cruzi in blood samples of patients suspected of Chagas disease infection. The kit, composed of a TaqMan duplex reaction targeting the T. cruzi satellite nuclear DNA and an exogenous internal amplification control, presented a reportable range from 104 to 0.5 parasite equivalents/mL and a limit of detection (LOD) of 0.16 parasite equivalents/mL of blood. In addition, the NAT Chagas kit detected T. cruzi belonging to all six discrete typing units (DTUs—TcI to TcVI), similarly to the in-house real-time PCR performed with commercial reagents, which has been selected as the best performance assay in the international consensus for the validation of qPCR for Chagas disease. In the clinical validation presented here, the kit showed 100% sensitivity and 100% specificity when compared to the consensus in-house real-time PCR assay. Thus, the NAT Chagas kit, which is produced entirely in Brazil under the international standards of good manufacturing practices (GMP), appears as an excellent alternative to enable the molecular diagnosis of Chagas disease in public and private diagnostic centers, as well as to facilitate the monitoring of patients under etiological treatment participating in clinical trials.
- Open Access
- 28 April 2022
- Published by MDPI AG in Preprints.org
The SARS-CoV-2 Omicron Variant of Concern and its Rapid Spread throughout the Western Brazilian Amazon
Genomic surveillance represents an important strategy for understanding evolutionary mechanisms, transmission profile, and infectivity of different SARS-CoV-2 variants. We assessed the epidemiological profile of 366 individuals who tested positive for SARS-CoV-2 from 29 municipalities in Rondônia between December 2021 to March 2022. Samples were collected, RNA was ex-tracted and screened using RT-qPCR for Alpha, Beta, Gamma, Delta and Omicron VOCs and viral quantification was performed. Sequences were analyzed for phylogeny, mutations and lineages. Of the samples analyzed, 93.71% were positive for the Omicron variant and 6.28% were positive for the Delta variant. The symptoms observed were cough, sore throat, and fever, with a mean duration of 5 days; no hospitalizations or deaths were reported. We noted that among the positive individuals, 51% had been immunized with two doses, 22% received three doses, 13% received one dose, and 13% were not immunized. Just 242 samples were amenable to analysis for alignment and phylogenetic characterization; corresponding to variants BA.1 and BA.1.1; a total of 120 mutations were identified, 36% of which were found in the S gene. In conclusion, there was a high frequency of mutations in the SARS-CoV-2 genome, but no record of clinical severity, demonstrating the positive effect of vaccination.
- 28 April 2022
- Published by MDPI AG in Preprints.org
Open AccessThe SARS-CoV-2 Omicron Variant of Concern and its Rapid Spread throughout the Western Brazilian Amazon
Genomic surveillance represents an important strategy for understanding evolutionary mechanisms, transmission profile, and infectivity of different SARS-CoV-2 variants. We assessed the epidemiological profile of 366 individuals who tested positive for SARS-CoV-2 from 29 municipalities in Rondônia between December 2021 to March 2022. Samples were collected, RNA was ex-tracted and screened using RT-qPCR for Alpha, Beta, Gamma, Delta and Omicron VOCs and viral quantification was performed. Sequences were analyzed for phylogeny, mutations and lineages. Of the samples analyzed, 93.71% were positive for the Omicron variant and 6.28% were positive for the Delta variant. The symptoms observed were cough, sore throat, and fever, with a mean duration of 5 days; no hospitalizations or deaths were reported. We noted that among the positive individuals, 51% had been immunized with two doses, 22% received three doses, 13% received one dose, and 13% were not immunized. Just 242 samples were amenable to analysis for alignment and phylogenetic characterization; corresponding to variants BA.1 and BA.1.1; a total of 120 mutations were identified, 36% of which were found in the S gene. In conclusion, there was a high frequency of mutations in the SARS-CoV-2 genome, but no record of clinical severity, demonstrating the positive effect of vaccination.